论文部分内容阅读
[目的]探讨MMP-9和VEGF在膀胱移行细胞癌(BTCC)发生发展过程中的表达意义及相关性。[方法]应用免疫组织化学方法检测65例膀胱移行细胞癌和10例癌旁正常组织中的MMP-9和VEGF表达,并分析其与临床病理参数间关系。[结果]MMP-9和VEGF在膀胱移行细胞癌组织中阳性表达率分别为47.69%(31/65)、58.46%(38/65),而在正常膀胱组织中均不表达或呈均匀分布的微量表达(P<0.05)。随着BTCC临床病理分期、分级的提高,MMP-9的表达水平呈现增高趋势(P<0.05)。MMP-9与VEGF呈正相关(r=0.392,P=0.008)。[结论]MMP-9和VEGF参与BTCC发生、发展过程,可作为评估BTCC预后的重要生物学指标之一。
[Objective] To investigate the significance of expression of MMP-9 and VEGF in the development of transitional cell carcinoma of bladder (BTCC). [Methods] The expressions of MMP-9 and VEGF in 65 cases of transitional cell carcinoma of bladder and 10 cases of normal tissues adjacent to cancer were detected by immunohistochemistry. The relationship between the expression of MMP-9 and clinicopathological parameters was analyzed. [Results] The positive rates of MMP-9 and VEGF in bladder transitional cell carcinoma were 47.69% (31/65) and 58.46% (38/65), respectively, but not in normal bladder tissues Micro-expression (P <0.05). With the clinicopathological stage and grade of BTCC, the expression level of MMP-9 showed an increasing trend (P <0.05). There was a positive correlation between MMP-9 and VEGF (r = 0.392, P = 0.008). [Conclusion] MMP-9 and VEGF are involved in the occurrence and development of BTCC and may be used as one of the important biological indexes to evaluate the prognosis of BTCC.